Simulations Plus Releases DILIsym® X
2024年8月1日 - 9:30PM
ビジネスワイヤ(英語)
Updated quantitative systems toxicology
(QST) software investigates and predicts drug-induced liver injury
(DILI)
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a
leading provider of biosimulation, simulation-enabled performance
and intelligence solutions, and medical communications to the
biopharma industry, has released the latest version of its flagship
quantitative systems toxicology (QST) platform, DILIsym® version
X.
“Modeling and predictions regarding drug efficacy are critical
in the drug development process—but so are predictions regarding
safety,” said Dr. Brett Howell, President of Quantitative Systems
Pharmacology (QSP) Solutions at Simulations Plus. “We know there is
often a gap between preclinical and clinical research toxicology
results, but DILIsym is designed to help researchers identify
potential DILI risks and, when appropriate, design dosing
strategies that can mitigate or eliminate possible hazards. With
the enhanced processing speed and improved user interface offered
by DSX, clients get crucial insight into the safety of their drug
candidate faster and more easily than ever before.”
Branded as DSX™, the software is designed to support key drug
development decisions by predicting potential drug-induced liver
injury (DILI) risks. These predictions can guide go/no-go
decisions, or the need to modify dosages, which are vital to
avoiding costly failed clinical trials.
Dr. Scott Q. Siler, Chief Scientific Officer of QSP Solutions at
Simulations Plus, added, “DSX will greatly enhance our clients’ and
our consulting group’s ability to quickly generate population-level
liver safety results that impact drug development decisions. This
faster turnaround time means fewer delays between critical safety
decision points, ensuring safe new drugs get to patients as rapidly
as possible while unsafe drug candidates can be discarded earlier
in the costly development process.”
DSX offers a completely redesigned interface, tested by clients
and consultants, that includes both command line and graphical
interface options as well as a licensing option that enables
scale-up on local or cloud cluster configurations. Four new
exemplar compounds are included in this version of the software, as
well as two new simulated populations that include variability in
susceptibility to liver injury and biomarker-related parameters
(ALT and bilirubin).
Learn more about DSX and request your evaluation license.
About Simulations Plus, Inc.
With more than 25 years of experience serving clients globally,
Simulations Plus stands as a premier provider in the biopharma
sector, offering advanced software and consulting services that
enhance drug discovery, development, research, clinical trial
operations, regulatory submissions, and commercialization. Our
comprehensive biosimulation solutions integrate artificial
intelligence/machine learning (AI/ML), physiologically based
pharmacokinetics (PBPK), quantitative systems
pharmacology/toxicology (QSP/QST), and population PK/PD modeling
approaches. We also deliver simulation-enabled performance and
intelligence solutions alongside medical communications support for
clinical and commercial drug development. Our cutting-edge
technology is licensed and utilized by leading pharmaceutical,
biotechnology, and regulatory agencies worldwide. For more
information, visit our website at www.simulations-plus.com. Follow
us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our website to read
our 2023 ESG update.
Forward-Looking Statements
Except for historical information, the matters discussed in this
press release are forward-looking statements that involve risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but there can
be no assurances that expected or anticipated results or events
will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or
contribute to such differences include, but are not limited to: our
ability to successfully integrate the recently acquired
Pro-ficiency business with our own, as well as expenses we may
incur in connection therewith, to maintain our competitive
advantages, acceptance of new software and improved versions of our
existing software, the general economics of the pharmaceutical
industry, market conditions, macroeconomic factors, and a
sustainable market. Further information on our risk factors is
contained in our quarterly and annual reports and filed with the
U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801802003/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Lisa Fortuna
310-622-8251 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
過去 株価チャート
から 7 2024 まで 8 2024
Simulations Plus (NASDAQ:SLP)
過去 株価チャート
から 8 2023 まで 8 2024